Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)
Public ClinicalTrials.gov record NCT03830866. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With and Following Chemoradiotherapy Compared to Chemoradiotherapy Alone for Treatment in Women With Locally Advanced Cervical Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a randomized, multi-center, double-blind, placebo-controlled, global, Phase III study to determine the efficacy and safety of durvalumab + Chemoradiotherapy versus Chemoradiotherapy alone as treatment in Women With Locally Advanced Cervical Cancer
Study identification
- NCT ID
- NCT03830866
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 770 participants
Conditions and interventions
Conditions
Interventions
- Durvalumab Biological
- Cisplatin Drug
- Carboplatin Drug
- external beam radiation therapy (EBRT) + brachytherapy Radiation
Biological · Drug · Radiation
Eligibility (public fields only)
- Age range
- 18 Years to 130 Years
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 15, 2019 (Actual)
- Primary completion
- Jan 20, 2022 (Actual)
- Completion
- Jul 3, 2023 (Actual)
- Last update posted
- Jul 26, 2024
2019 – 2023
United States locations
- U.S. sites
- 16
- U.S. states
- 9
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Phoenix | Arizona | 85016 | — |
| Research Site | La Jolla | California | 92093 | — |
| Research Site | Orange | California | 92868 | — |
| Research Site | Fort Myers | Florida | 33905 | — |
| Research Site | Miami | Florida | 33136 | — |
| Research Site | Augusta | Georgia | 30912 | — |
| Research Site | Ann Arbor | Michigan | 48109 | — |
| Research Site | Lake Success | New York | 11042 | — |
| Research Site | The Bronx | New York | 10461 | — |
| Research Site | Cleveland | Ohio | 44111 | — |
| Research Site | Cleveland | Ohio | 44124 | — |
| Research Site | Cleveland | Ohio | 44195 | — |
| Research Site | Nashville | Tennessee | 37203 | — |
| Research Site | Dallas | Texas | 75235 | — |
| Research Site | Dallas | Texas | 75390 | — |
| Research Site | Spring | Texas | 77380 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 101 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03830866, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 26, 2024 · Synced Oct 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03830866 live on ClinicalTrials.gov.